menu
    • menu
    [{"orgOrder":0,"company":"ArsenalBio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Next-generation T cell therapies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"ArsenalBio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ArsenalBio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"ArsenalBio \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"ArsenalBio","sponsor":"Softbank Vision Fund 2","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Series B Financing","leadProduct":"AB-1015","moa":"CTLA-4x\/OX40","graph1":"Oncology","graph2":"IND Enabling","graph3":"ArsenalBio","amount2":0.22,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.22,"dosageForm":"","sponsorNew":"ArsenalBio \/ Softbank Vision Fund 2","highestDevelopmentStatusID":"5","companyTruncated":"ArsenalBio \/ Softbank Vision Fund 2"},{"orgOrder":0,"company":"ArsenalBio","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"T-cell Based Therapeutic","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"ArsenalBio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ArsenalBio \/ Genentech","highestDevelopmentStatusID":"2","companyTruncated":"ArsenalBio \/ Genentech"},{"orgOrder":0,"company":"ArsenalBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"AB-1015","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"ArsenalBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ArsenalBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ArsenalBio \/ Not Applicable"},{"orgOrder":0,"company":"ArsenalBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"AB-2100","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ArsenalBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ArsenalBio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ArsenalBio \/ Not Applicable"},{"orgOrder":0,"company":"ArsenalBio","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Series C Financing","leadProduct":"AB-2100","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ArsenalBio","amount2":0.33000000000000002,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ArsenalBio \/ ARCH Venture Partners","highestDevelopmentStatusID":"14","companyTruncated":"ArsenalBio \/ ARCH Venture Partners"}]

    Find Clinical Drug Pipeline Developments & Deals by ArsenalBio

    Menu

    ArsenalBio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ArsenalBio

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            ArsenalBio

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AB-2100

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : ARCH Venture Partners

                            Deal Size : $325.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            ArsenalBio Secures $325M Financing to Boost Programmable Cell Therapy Development

                            Details : The Proceeds from the financing will be used to advance ArsenalBio’s lead program AB-2100, an engineered ICT cell therapy for treating clear-cell renal cell carcinoma.

                            Brand Name : AB-2100

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 04, 2024

                            Lead Product(s) : AB-2100

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : ARCH Venture Partners

                            Deal Size : $325.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ArsenalBio

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            ArsenalBio

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AB-2100

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Arsenal Biosciences Doses First Patient in Phase 1/2 Trial of AB-2100 for Kidney Cancer

                            Details : AB-2100, an engineered ICT cell therapy, is presently undergoing evaluation in Phase 1/2 clinical trial studies with patients for treating clear-cell renal cell carcinoma.

                            Brand Name : AB-2100

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            April 30, 2024

                            Lead Product(s) : AB-2100

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ArsenalBio

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            ArsenalBio

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AB-1015

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ArsenalBio Announces First Patient Dosed in Phase 1 Clinical Trial of AB-1015 in Development as a Treatment fo...

                            Details : AB-1015 is ArsenalBio’s first internally discovered T cell medicine to enter clinical development and uses synthetic DNA programming to overcome tumor defenses, increase potency, and target ovarian cancer cells without harming normal tissues.

                            Brand Name : AB-1015

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            January 05, 2023

                            Lead Product(s) : AB-1015

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ArsenalBio

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            ArsenalBio

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : T-cell Based Therapeutic

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Genentech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Arsenal Biosciences Announces Joint Discovery Collaboration with Genentech to Identify Features of Successful ...

                            Details : Under the terms of the collaboration, ArsenalBio and Genentech will deploy synergistic capabilities to study effective T cell-based modifications and develop new understandings of their effects through preclinical analysis.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $70.0 million

                            September 27, 2022

                            Lead Product(s) : T-cell Based Therapeutic

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Genentech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ArsenalBio

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            ArsenalBio

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AB-1015

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Softbank Vision Fund 2

                            Deal Size : $220.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Arsenal Biosciences Closes $220 Million Series B Financing to Advance Programmable Cell Therapy Programs into ...

                            Details : The fundraising comes as the company begins planning for clinical trials of its lead program AB-1015, an ovarian cancer candidate for which FDA IND clearance and first patient dosing are targeted for later this year.

                            Brand Name : AB-1015

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 06, 2022

                            Lead Product(s) : AB-1015

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Softbank Vision Fund 2

                            Deal Size : $220.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ArsenalBio

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            ArsenalBio

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Next-generation T cell therapies

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            ArsenalBio Announces Multi-Program Discovery Collaboration with Bristol Myers Squibb

                            Details : ArsenalBio will deploy its full stack of synthetic biology compositions to build programmable cell therapy product candidates, composed of its PrimeR™ logic gates, CARchitecture™ derived gene expression controls, and CellFoundry™ mediated nonviral ...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $70.0 million

                            January 07, 2021

                            Lead Product(s) : Next-generation T cell therapies

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth